

Association of Hemoglobin A_{1c} level with the severity of coronary artery disease in female patients with metabolic Syndrome

Thesis

Submitted for partial fulfillment of
master degree in cardiology

Presented by

Mostafa Abd EL-Tawwab Abd EL-Reheem
M.B.B.Ch

Under supervision of

Professor Doctor: Sameh Mohammed Shaheen

Professor of cardiology
Faculty of medicine
Ain shams university

Doctor: Ramy Raymond Elias

Lecturer of cardiology
Faculty of medicine
Ain shams university

Faculty of medicine
Ain shams university

2009

بسم الله الرحمن الرحيم

قُلْ إِنِّي خَلَّيْتُ وَنُكَيْتِي وَمَخْيَلِي
وَمَمَاتِي لِلَّهِ رَبِّ الْعَالَمِينَ (162) لَا
شَرِيكَ لَهُ وَبِذَلِكَ أُمِرْتُ وَأَنَا أَوَّلُ
الْمُسْلِمِينَ (163)

صدق الله العظيم

سورة الانعام
الآية (162 - 163)

Acknowledgment

First of all, I would like to thank, ALLAH who wanted life for this work.

I would like to express my profound gratitude and sincere appreciation to Dr. Sameh Mohammed Shaheen, professor of cardiology department, Faculty of Medicine, Ain Shams University who gave me the privilege of working under his supervision. To him no words of thanks or gratitude are sufficient.

My sincere appreciation goes to Dr. Ramy Raymond Elias, Lecturer of cardiology, Faculty of Medicine, Ain Shams University for his precious advices. Kindly he supplied me with all necessary facilities for success.

Last but not least, I have to add my love and profound appreciation for my family for their support and forbearance.



DEDICATION ...

TO

My Family

Contents

Title	Page
☞ List of figures	ii
☞ List of tables	iv
☞ List of abbreviations	vi
☞ <i>Introduction</i>	1
☞ <i>Aim of the work</i>	4
☞ <i>Review of literature</i>	5
☞ <i>I- Metabolic Syndrome</i>	5
☞ <i>II- Atherosclerosis</i>	27
☞ <i>III- Haemoglobin A1c</i>	47
☞ <i>Patients and Methods</i>	56
☞ <i>Results</i>	62
☞ <i>Discussion</i>	79
☞ <i>Conclusion and recommendations</i>	91
☞ <i>Limitations of the study</i>	92
☞ <i>Summary</i>	93
☞ <i>References</i>	97
☞ <i>Arabic Summary</i>	-

List of Figures

No.	Title	page
1	Effects of metformin on fibrinolysis, coagulation, and blood viscosity.	23
2	Schematic evolution of the atherosclerotic lesion.	34
3	History of DM among study group.	64
4	History of HTN among study group.	64
5	Positive family history among study group.	65
6	Dyslipidemia among study group.	65
7	Lipid profile among study group.	67
8	Coronary angiography results among study group.	71
9	HbA _{1c} level and number of vessels stenosed > 50 %.	71
10	Relation of BMI and number of vessels stenosed > 50%.	73
11	Relation of waist circumference and number of vessels stenosed 50%.	73
12	Relation of age and number of vessels stenosed > 50%.	74

No.	Title	page
13	Relation of Total cholesterol and number of vessels stenosed > 50%.	76
14	Relation of HDL and number of vessels stenosed > 50%.	76
15	Relation of LDL and number of vessels stenosed > 50%.	77
16	Relation of triglyceride and number of vessels stenosed >50%.	77
17	Relation of FBS and number of vessels stenosed >50 %.	78

List of Tables

No.	Title	page
1	Metabolic syndrome: proposed components and associated findings.	10
2	Diagnostic criteria for the metabolic syndrome.	16
3	EGIR criteria diagnostic for metabolic Syndrome.	17
4	Effect of hypoglycemic agents on cardiovascular risk factors.	24
5	Key steps in atherosclerosis highlighting role of Inflammation at various steps.	30
6	The American Heart Association: six stages characterize plaque evolution.	32
7	Infectious organisms implicating atherosclerosis.	46
8	Mean age, waist circumference and BMI among study group.	62
9	Risk factors among study group.	63
10	Lipid profile among study group.	66

No.	Title	page
11	Mean FBS and HbA1c among study group.	67
12	Mean HbA1c level in patients with and without history of diabetes.	68
13	Mean HbA1c level in patients with and without history of HTN.	68
14	Angiography results among study group.	69
15	Association of HbA1c level with severity of coronary artery disease.	70
16	Mean BMI, waist circumference and age and severity of coronary artery disease.	72
17	Mean lipid profile and severity of coronary artery disease.	75
18	Mean FBS and severity of coronary artery disease.	78

List of Abbreviations

2-h PPG	2-hour postprandial glucose.
AACE	American Association of Clinical Endocrinologists.
ACE	Angiotensin converting enzyme.
ADA	American Diabetes Association.
AGE	Advanced glycation end product.
AHA/NHLBI	American Heart Association/ National Heart Lung Blood Institution.
ALT	Alanine transaminase.
AMP 1	Adiponectin gene.
ARBs	Angiotensin receptor blockers.
BMI	Body mass index.
CAD	Coronary artery disease.
CAMs	Cell adhesion molecules.

CHD	Coronary heart disease.
CMV	Cytomegalovirus
CP	Chlamydia pneumoniae.
CRP	C-reactive protein.
CVD	Cardiovascular disease.
MMIMT	Mean maximal intima media thickness.
DCCT	Diabetic Control and Complication Trial.
DM	Diabetes mellitus.
EDTA	Ethylene diamine trisodium acetate.
EGIR	European Group for study of Insulin Resistance.
EL	Endothelial lipase.
FBS	Fasting blood sugar.
FPG	Fasting plasma glucose.
GHb	Glycated hemoglobin.

H.pyloi	Helicobacter pylori.
HbA1c	Hemoglobin A1c.
HDL-C	High density lipoprotein-cholesterol.
HOMA_{IR}	Homeostatic model assessment of insulin resistance.
HTN	Hypertension.
ICAM	Intercellular adhesion molecule.
IDF	International Diabetes Federation.
IDL	Intermediate density lipoprotein.
IFG	Impaired fasting glucose.
IGT	Impaired glucose tolerance.
IHD	Ischemic heart disease.
IL-8	Interlukin-8.
ILs	Interleukins.
IR	Insulin resistance.

LDL-C	Low density lipoprotein cholesterol.
LDL-P	Low density lipoprotein-particle.
LP	Lipoprotein.
Lp-PLA2	Lipoprotein associated phospholipase A2.
LV	Left ventricle.
Lyso-PC	Lysophosphatidylchoine.
MCP-1	Monocyte chemoattractant protein-1.
M-CSF	Macrophage -Colony stimulating factor.
NAFLD	Non alcoholic fatty liver disease.
NCEP-ATP	National Cholesterol Education Program- Adult Treatment Panel.
NGSP	National glycohemoglobin standarization program.
ox-NEFA	Oxidized nonesterified fatty acid.
PAD	Peripheral arterial disease.

PAI-1	Plasminogen activator-inhibitor-1.
PCOS	Polycystic ovary syndrome.
PPARs	Peroxisome proliferator-activated receptors.
PPG	Postprandial glucose.
RAGE	Receptor for advanced glycation end product.
RBC	Red blood cell.
SD	Standard deviation.
TC	Total cholesterol.
TG	Triglycerides.
TNF α	Tumour necrosis factor- α .
tPA	Tissue plasminogen activator.
TZDs	Thiazolidinediones.
UAE	United Arab Emirates.
US	United States Of America.